The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
 
Ai-Ping Zhou
No Relationships to Disclose
 
Jianhui Ma
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Yan Song
No Relationships to Disclose
 
Hangzhong Li
No Relationships to Disclose
 
Xiaodong Xie
No Relationships to Disclose
 
Xiu-Bao Ren
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose
 
Jiyan Liu
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Xianzhong Bai
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Cheng Fu
No Relationships to Disclose
 
Jinwan Wang
No Relationships to Disclose